Translation, cross‐cultural adaptation, and validation of the chinese version of the 15‐item myasthenia gravis quality of life questionnaire

Miao, Xiaoqing; Lian, Zhiyun; Liu, Ju; Chen, Hongxi; Shi, Ziyan; Li, Mier; Zhou, Hongyu; Hu, Xiuying; Yang, Rong

doi:10.1002/mus.26313

Cited by 7 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Total HAM-D scores were classified as no (< 7), potential (7-17), assured (17-24), and severe (> 24) depression, the Cronbach’s coefficient of them was > 0.8, indicating good internal consistency. The above questionnaires and scales were administered in the Chinese language, and are all reliable, valid, and widely used[ 30 - 33 ].…”

Section: Methodsmentioning

confidence: 99%

Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients

Yu¹,

Li²,

Ran³

et al. 2022

WJP

View full text Add to dashboard Cite

BACKGROUND Mental disorders are common comorbidities among individuals with neurological diseases, and the prevalence of depressive and anxiety-related symptoms in newly referred patients at neurology outpatient clinics is high. There have been few studies on the mental health of patients with late-onset myasthenia gravis (MG). AIM To examine the relationship between clinical features and the mental health symptoms within late-onset MG patients. METHODS A total of 105 patients diagnosed with MG were recruited consecutively from a neuromuscular outpatient clinic between December 2020 and February 2021. Patients were classified into two groups: early-onset MG (age at onset < 50 years, n = 63) and late-onset MG (age at onset ≥ 50 years, n = 42). Social demographic data and information about marital status, education level, clinical symptoms, serum antibody levels, and therapies used were collected for all participants. Participants were also evaluated using the Myasthenia Gravis Composite scale, the Myasthenia Gravis Activities of Daily Living scale, the Myasthenia Gravis Quality of Life 15 (MG-QOL-15) questionnaire, the 17-item version of the Hamilton Depression Rating Scale (HAM-D) and the Hamilton Anxiety Rating Scale (HAM-A). The relationship between clinical features and mental health in late-onset MG patients was examined using multivariate logistic regression analyses. RESULTS Late-onset MG patients were more prone to dyspnea, had higher levels of serum anti-acetylcholine receptor antibodies, and higher total scores on the MG-QOL-15, HAM-D, and HAM-A questionnaires, than early-onset MG patients had ( P < 0.05). Among those with late-onset MG, female patients had higher total HAM-D and HAM-A scores than male patients had ( P < 0.05). High scores on the QOL-15 questionnaire were associated with higher incidences of anxiety and depression, and the association was found to be independent after adjusting for confounding risk factors. In the late-onset subgroup, the areas under the receiver operating characteristic curves for the MG-QOL-15 score-based diagnostic accuracy for anxiety and depression state were 0.816 ( P = 0.001) and 0.983 ( P < 0.001), respectively. CONCLUSION Higher MG-QOL-15 scores were a risk factor for anxiety and depression in late-onset MG, and women with late-onset MG were more likely to have anxiety and depression than men were.

show abstract

Section: Methodsmentioning

confidence: 99%

Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients

Yu¹,

Li²,

Ran³

et al. 2022

WJP

View full text Add to dashboard Cite

show abstract

“…The 15‐item MG‐specific QOL scale (MG‐QOL15) was created as a useful measure convenient for informing physicians about the patient’s perception of MG‐related dysfunction 11‐13 . The MG‐QOL15 consists of just 15 simple questions, and appears to be not only user‐friendly 11‐13 for English‐speaking patients, but also, even when translated into other languages, it is easy to use without a significant effect of cultural differences 5,14‐17 . As we had no MG‐specific QOL scale in Japanese, we prepared a Japanese version of the MG‐QOL15 (MG‐QOL15‐J), and investigated its reliability and validity for Japanese patients 5 .…”

Section: Introductionmentioning

confidence: 99%

“…As we had no MG‐specific QOL scale in Japanese, we prepared a Japanese version of the MG‐QOL15 (MG‐QOL15‐J), and investigated its reliability and validity for Japanese patients 5 . MG‐QOL15 has been translated and validated in a variety of languages 5,14‐17 . During assessments of associations between MG‐QOL15 and detailed clinical information from our survey in 2010 to validate the scale, we noticed several important points warranting clarification in order to improve the QOL of MG patients 5 …”

Section: Introductionmentioning

confidence: 99%

“…[11][12][13] The MG-QOL15 consists of just 15 simple questions, and appears to be not only user-friendly [11][12][13] for English-speaking patients, but also, even when translated into other languages, it is easy to use without a significant effect of cultural differences. 5,[14][15][16][17] As we had no MGspecific QOL scale in Japanese, we prepared a Japanese version of the MG-QOL15 (MG-QOL15-J), and investigated its reliability and validity for Japanese patients. 5 MG-QOL15 has been translated and validated in a variety of languages.…”

mentioning

confidence: 99%

“…5 MG-QOL15 has been translated and validated in a variety of languages. 5,[14][15][16][17] During assessments of associations between MG-QOL15 and detailed clinical information from our survey in 2010 to validate the scale, we noticed several important points warranting clarification in order to improve the QOL of MG patients. 5 In addition to a 2010 survey, 5,18 we carried out further multicenter surveys in 2012 6,[19][20][21] and 2015, [22][23][24] and obtained detailed quantitative data and some longitudinal clinical information from a total of 1890 patients with established MG. By analyzing such data, we clarified the actual condition of MG patients, 5,6,[18][19][20][21] determined major factors that negatively affect patient QOL, 5,6,18 recommended an appropriate treatment target to achieve good QOL, 5,6 and proposed treatment strategies to enable MG patients to achieve the target early and live a normal lifestyle.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Health‐related quality of life and treatment strategies in myasthenia gravis

Utsugisawa

Nagane

Uzawa

et al. 2020

Clinical & Exp Neuroim

View full text Add to dashboard Cite

The spread of immune treatments based on oral steroids since the 1970s has led to a non-lethal disease course and decreased severity of illness for many patients with myasthenia gravis (MG). 1-6 However, the rate of long-term complete stable remission (CSR) has not been increased and remains quite low. 1-6 Even today, many patients experience difficulties with daily activities as a result of residual fatigability and long-term side-effects of medications, such as oral steroids, and they are unable to live a normal lifestyle. 1,2,5,6 Such conditions negatively influence health-related quality of life (QOL). 5-8 In Japan until the 2000s, a considerable proportion of neurologists were content with the better clinical symptoms after immune treatment and the preferable condition compared with the period when MG had been a severe disease with a high mortality rate. MG symptoms fluctuate and limit the utility of measuring disease status based solely on simple examination during clinical visits. 9,10 Given the delay in the adoption of quantitative estimation of fatigability

show abstract

Utilization of MG‐ADL in myasthenia gravis clinical research and care

Muppidi

Silvestri

Tan³

et al. 2022

Muscle and Nerve

View full text Add to dashboard Cite

The Myasthenia Gravis Activities of Living (MG‐ADL) scale is an 8‐item patient‐reported scale that measures myasthenia gravis (MG) symptoms and functional status. The objective of the current review is to summarize the psychometric properties of the MG‐ADL and published evidence of MG‐ADL use. A targeted literature review for published studies of the MG‐ADL was conducted using a database and gray literature search. A total of 48 publications and 35 clinical trials were included. Studies indicated that the MG‐ADL is a reliable and valid measure that has been used as an outcome in clinical trials and observational studies to measure MG symptoms and response to treatment. While most often used as a secondary endpoint in clinical trials, its use as a primary endpoint has increased in recent years. The most common MG‐ADL endpoint is change in MG‐ADL score from baseline, although there has been an increase in the analysis of a responder threshold using the MG‐ADL. A new concept of minimal symptom expression (MSE) has emerged more recently. Duration of treatment effect is another important construct that is being increasingly evaluated using the MG‐ADL. The use of the MG‐ADL as a primary endpoint in clinical trials and in responder threshold analyses to indicate treatment improvement has increased in recent years. MSE using the MG‐ADL shows promise in helping to determine success of treatment and may be the aspirational goal of MG treatment for the future once validated, particularly given the evolving treatment landscape in MG.

show abstract

Translation, cross‐cultural adaptation, and validation of the chinese version of the 15‐item myasthenia gravis quality of life questionnaire

Abstract: The Chinese MG-QOL15 showed comparable construct, discriminant and concurrent validity, and internal consistency with to the original version.

Cited by 7 publications

References 33 publications

Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients

Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients

Health‐related quality of life and treatment strategies in myasthenia gravis

Utilization of MG‐ADL in myasthenia gravis clinical research and care

Contact Info

Product

Resources

About